Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Hunterian Medicine

Main focus: Gene editing for the treatment of genetic diseases

Company stage: Pre-clinical

Diseases (gene editing): Undisclosed

Genome editing tool: CRISPR-MAD7, other undisclosed

Funding stage: Private

Location: Cambridge, MA, USA


Partners: Inscripta

Hunterian Medicine aims to enable CRISPR delivery within the limited AAV packaging capacity that currently represents one of the major challenges within therapeutic genome editing. The company is exploring a range of diseases and orphan indications for licensing and/or development, although it has yet to disclose targets and indications for its lead therapeutic programme.


HashtagHunterian Medicine

Company: Hunterian Medicine
Search CRISPR Medicine